WHO chief reiterates 'act together' as UK approves Pfizer-BioNtech’s COVID-19 vaccine

World Health Organisation chief, Tedros ham Ghebreyesus, on December 2 welcomed encouraging news from United Kingdom as country approves Pfizer-BioNtech’s COVID-19 vaccine candidate for widespre use. British regulator MHRA has anunced that mRNA-based vaccine that showed 95% efficacy, is safe for mass roll out with immunisations in country starting "early next week" among  high priority groups. Britain has reportedly alrey placed an order of 40 million doses of Pfizer-BioNTech's COVID-19 vaccine to provide double-dose immunisation to at least 20 million people. 

While taking to Twitter, Tedros reiterated to “act toger” and said, “ UK is first country to authorize Pfizer/BionTech #COVID19 vaccine for emergency use and expects to start rolling it out as soon as next week #ACTogr. 

RE: Pfizer CEO Hails 'historic Moment' In Fight Against COVID-19 As UK Authorises Its Vaccine

As per reports, nearly 10 million doses of vaccine candidate, BNT162b2 will be available for UK shortly. COVID-19 vaccine w approved by UK is also one of fastest ever vaccine to become a reality from just a concept as it took only 10 months for a process that could rmally take up to a dece. Even though vaccination will begin soon in Britain, people would still be asked to remain cautious and follow government proposed COVID-19 guidelines.

" Government has today accepted recommendation from Independent Medicines and Healthcare products Regulatory ncy (MHRA) to approve Pfizer-BioNTech’s COVID-19 vaccine for use. This follows months of rigorous clinical trials and a thorough analysis of data by experts at MHRA who have concluded that vaccine has met its strict standards of safety, quality and effectiveness," UK government said in a statement.

RE: ' Best News EVER!': Kevin Pietersen Makes Demand As UK Clears Pfizer's Covid-19 Vaccine

All About Pfizer-BioNTech's Covid Vaccine

Pfizer's vaccine has been demonstrated to be 95% effective against Covid 28 days after first dose (i.e. 7 days after second dose)

i.e. Dose 1 + 21 days + Dose 2 + 7 days -> 95% efficacy

results were published after conclusion of phase 3 study which enrolled 43,661 participants. It found 170 confirmed cases of COVID-19, with 162 observed in placebo group (those who didn't get vaccine) versus 8 in vaccine group.

Pfizer's stor plan is that it has 'developed specially designed, temperature-controlled rmal shippers, utilizing dry ice to maintain temperature conditions of -70°C±10°C. y can be used be as temporary stor units for 15 days by refilling with dry ice.' Essentially, however, vaccine in its current form needs to be stored at -70°C.

RE: UK Approves Pfizer-BioNTech's COVID Vaccine For Mass Rollout, Iculation Begins Next Week

RE: BioNtech-Pfizer File 'formal Application' Seeking EU Approval For Its COVID-19 Vaccine